Do Thi Quynh, Vu Van Nga, Le Thi Hoa, Le Thi Hong Diem, Vu Thi Thom

Main Article Content


Cardiovascular disease is the leading cause of death in the world. Cardiovascular risk assessment is an important step in preventing and treating the disease. The current study assesses the 10-year risk of cardiovascular disease in 306 VNU’s office workers in 2016-2017 based on the 2008 Framingham Risk Score. The study results show that the average risk score was 4.05 ± 4.76%; low risk was 90.52%; moderate risk: 7.85 %; and high to very high risk was 1.63%. Men have a higher risk score than women (p <0.001). The ten-year cardiovascular risk score shows that age and systolic blood pressure correlated with the risk at a medium level, and cholesterol and HDL correlated with it at a low level.


Framingham Risk Score 2008, 10-year cardiovascular risk score, hypertension, blood cholesterol, blood HDL.


[1] Cardiovasculardiseases, diseases-(cvds), (truy cập ngày 22/03/2019).
[2] A.R. Gregory et al, Global, regional, and national burden of cardiovascular diseases for 10 Causes, 1990 to 2015, Journal of the American college of cardiology. 70(1) (2017) 1–25.
[3] E. Gresham, T.E. Fitzpatrick, P.A. Wolf et al, Residual disability in survivors of stroke--the Framingham study, N Engl J Med. 293(19) (1975) 954–956.
[4] T.A. Pearson, S.N. Blair, S.R. Danielset et al, AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases, American heart association science advisory and coordinating committee, Circulation. 106(3) (2002) 388–391.
[5] I. Graham, D. Atar, K. B. Johnsen et al, European guidelines on cardiovascular disease prevention in clinical practice: full text - Fourth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice constituted by representatives of nine societies and by invited experts, Euro heart J. 28(19) (2007) 2375-2414.
[6] S.S. Mahmood, D. Levy, R.S. Vasanet et al, The Framingham heart study and the epidemiology of cardiovascular diseases: a historical perspective, Lancet. 383(9921) (2014) 999–1008.
[7] J.A.A.G. Damen, L. Hooft, E. Schuit et al, Prediction models for cardiovascular disease risk in the general population: systematic review, BMJ. 353(2016) 1-10.
[8] L.Q.H. Goh, T.A. Welborn, S.S. Dhaliwal, Independent external validation of cardiovascular disease mortality in women utilising Framingham and SCORE risk models: a mortality follow-up study, BMC women health. 14 (2014) 118-129.
[9] L.M. A. Rodenas, J.A. C. Herencia, J.A. D. Garrote et al, Framingham risk score for prediction of cardiovascular diseases: a population-based study from southern Europe, PLoS One. 8(9) (2013) 1-10.
[10] G.M. Park, Y.H. Kim, Model for predicting cardiovascular disease: insights from a Korean cardiovascular risk model, Pulse (Basel). 3(2) (2015) 153–157.
[11] Trần Kim Trang, Nguy cơ 10 năm của bệnh tim mạch ở nữ giới tăng huyết áp, Y học thành phố Hồ Chí Minh. 16(1) (2012) 181-185.
[12] Trương Thanh Sơn, Nguyễn Văn Trí, Trương Quang Bình, Nghiên cứu áp dụng thang điểm Framingham nhằm định nguy cơ bệnh động mạch vành trong 10 năm tới tại bệnh viện đa khóa Bình Dương, Y học thành phố Hồ Chí Minh. 15(1) (2011) 207-212.
[13] Nguyễn Thị Kim Thủy, Dự báo nguy cơ mắc bệnh động mạch vành trong 10 năm theo thang điểm Frammingham ở bệnh nhân tăng huyết áp nguyên phát, Y học thực hành. 802(1) (2012) 27-29.
[14] Nguyễn Hồng Huệ, Nguyễn Đức Công, Nghiên cứu ước tính nguy cơ bệnh động mạch vành trong 10 năm tới theo thang điểm Framingham qua 500 trường hợp, Y học thành phố Hồ Chí Minh. 15(2) (2011) 38-44.
[15] C.V. Aram et al, The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure, National heart, lung and blood institute - National institutes of health, NIH publication no. 04-5230, US, (2014), pp 13.
[16] National Heart, Lung and Blood Institute, Third Report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel III) Final report, National institutes of health, part II, US, (2002), pp 5-10.
[17] World Health Organization, The Asia-Pacific perspective: redefining obesity and its treatment, Geneva: World health organization western pacific regional office, (2000), 18-19.
[18] N.Q. Nguyen, S.T. Pham, L.D. Do et al, Cardiovascular disease risk factor patterns and their implications for intervention strategies in Vietnam, Int J Hypertens, ID. 560397, (2012), 1-11.
[19] M. Nakhaie, B. Koor, S. Salehiet al, Prediction of cardiovascular disease risk using framingham risk score among office workers, Iran, 2017, Saudi journal of kidney diseases and transplantation. 29(3) (2018) 608-614.
[20] Trịnh Xuân Thắng, Nghiên cứu các yếu tố nguy cơ bệnh tim mạch ở người >25 tuổi tại 2 quận huyện Hà Nội, Luận văn thạc sỹ, Đại học Y Hà Nội, (2013).
[21] Nguyễn Hoàng Liên, Văn Thế Trung, Xác định nguy cơ tim mạch theo thang điểm Framingham trên bệnh nhân vẩy nến tại bệnh viện da liễu TP. Hồ Chí Minh, Y Học TP. Hồ Chí Minh, 18(1), (2014), 79-85.
[22] R. Gupta, V. Kaul, A. Agrawalet et al, Cardiovascular risk according to educational status in India, Preventive medicine. 51(5) (2010) 408–411.
[23] C.A. Jones, L. Ross, N. Suraniet al, Framingham ten-year general cardiovascular disease risk: agreement between BMI-based and cholesterol-based estimates in a South Asian convenience sample, PLOS ONE. 10(3) (2015) e0119183.
[24] K.S. Tyrrell, H.C. Lassila, E. Meilahn et al, Carotid atherosclerosis in premenopausal and postmenopausal women and its association with risk factors measured after menopause, Stroke. 29(6) (1998) 1116–1121.
[25] Margaret Kelly Hayes et al, Influence of age and health behaviors on stroke risk: lessons from longitudinal studies, J Am Geriatr Soc. 58(2) (2010) 325–328.
[26] D. Sugiyama, T. Okamura, M. Watanabe et al, Risk of hypercholesterolemia for cardiovascular disease and the population attributable fraction in a 24-year Japanese cohort study, J Atheroscler Thromb. 22(1) (2015) 95–107.
[27] M.R. Law, N.J. Wald, S.G. Thompson, By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease, BMJ. 308(6925) (1994) 367–372.
[28] Abolfazl Mohammadbeigi et al, Dyslipidemia prevalence in Iranian adult men: the impact of population-based screening on the detection of undiagnosed patients, World J men health. 33(3) (2015) 167-173.
[29] R.S. Joshi et al, Prevalence of dyslipidemia in urban and rural India: The ICMR–INDIAB Study, PloS ONE. 9(5) (2014) 1-9.
[30] Wichai Aekplakorn et al, Prevalence of dyslipidemia and management in the Thai population: national health examination survey IV, 2009, Journal of lipids. (2014) 1-13.
[31] Asia Pacific, Cohort Studies Collaboration, cholesterol, diabetes and major cardiovascular diseases in the Asia-pacific region, Diabetologia. 50(11) (2003) 2289-2297.
[32] S. Lewington, R. Clarke, N. Qizilbash, R. Peto, R. Collins et al, Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies, Lancet. 360(9349) (2002) 1903–1913.
[33] Viet Nam national STEPS Survey 2015,, (2015), (truy cập ngày 09/03/2019).
[34] Nguyễn Lân Việt, Kết quả mới nhất điều tra tăng huyết áp toàn quốc năm 2015 – 2016, Hội tim mạch Việt Nam,, (2016) (truy cập ngày 11/02/2019).
[35] M. Satoh, et al, Combined effect of blood pressure and total cholesterol levels on long-term risks of subtypes of cardiovascular death: evidence for cardiovascular prevention from observational cohorts in Japan, hypertension. 65(3) (2015) 517–524.